PhIII lung cancer data signal potential approval for AstraZeneca's Imfinzi
The data on AstraZeneca’s Phase III Imfinzi trial are out, and it bodes well for the UK outfit’s bid to get their signature immunotherapy approved for frontline small-cell lung cancer (SCLC).
Patients receiving the PD-L1 Imfinzi (alongside a standard chemotherapy regimen) in AstraZeneca’s CASPIAN study survived for 13 months on average, compared with 10.3 months for patients receiving the standard of care. Those numbers compare favorably to the results of the pivotal study that pushed Roche’s PD-L1 Tecentriq across the finish line. Tecentriq patients had an OS of 12.3 months in that study, which was announced six months before the FDA approved the drug for frontline SCLC.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.